Paricalcitol

Vitamin D Analog — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

Key facts

Paricalcitol is an ofp drug in the Vitamin D Analog class catalogued in DrugCentral. It was first approved by the FDA in 1998. DrugCentral lists 1 molecular target, including VDR. Recorded indications include Hyperparathyroidism Secondary to Chronic Renal Failure.

• Approval status: ofp (first approved 1998 by the FDA).
• Drug class: Vitamin D Analog; Vitamin D2 Analog.
• Molecular targets: VDR (1 listed in DrugCentral).
• Indications: Hyperparathyroidism Secondary to Chronic Renal Failure.
• ATC code: H05BX02 (Other anti-parathyroid agents).
• Molecular formula: C27H44O3; molecular weight 416.65 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Hyperparathyroidism Secondary to Chronic Renal Failure

Contraindications (4)

• Hypercalcemia
• Hyperphosphatemia
• Hypervitaminosis D
• Poisoning by digitalis glycoside

Mechanism & targets

• Established pharmacologic class: Vitamin D Analog; Vitamin D2 Analog

Molecular targets (1)

Target	Gene	Action	Activity
Vitamin D3 receptor	VDR	agonist	EC50 8.70

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1998-04-17	FDA	—	ABBVIE	Yes

ATC classification

ATC code	Therapeutic hierarchy
H05BX02	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › CALCIUM HOMEOSTASIS › ANTI-PARATHYROID AGENTS › Other anti-parathyroid agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Death	7755.5
Cardiac disorder	1264.7
Infarction	874.2
Myocardial infarction	613.6
Sepsis	458.0
Cardiovascular disorder	407.0
Cardiac failure	374.5
Respiratory arrest	336.9
Cardio-respiratory arrest	335.1
Calciphylaxis	292.8
Adverse event	273.7
Renal transplant	231.5

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Paricalcitol is on its molecule page.

• Molecular formula: C₂₇H₄₄O₃
• Molecular weight: 416.65 g/mol
• CAS number: 131918-61-1
• InChIKey: BPKAHTKRCLCHEA-UBFJEZKGSA-N
• PubChem CID: 5281104

C[C@H](\C=C\[C@H](C)C(C)(C)O)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C1C[C@@H](O)C[C@H](O)C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Paricalcitol used for?

DrugCentral lists the following indications for Paricalcitol: Hyperparathyroidism Secondary to Chronic Renal Failure.

How does Paricalcitol work?

Its molecular targets in DrugCentral include VDR (agonist).

When was Paricalcitol first approved?

Paricalcitol was first approved by the FDA in 1998.

What drug class does Paricalcitol belong to?

Paricalcitol is in the Vitamin D Analog class.

What is the chemical formula of Paricalcitol?

Paricalcitol has the molecular formula C27H44O3 and a molecular weight of 416.65 g/mol.

Sources

• DrugCentral drug card 2066 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200622 — compound record and bioactivity
• PubChem CID 5281104 — chemical identifiers
• DrugBank DB00910 — drug record
• FDA UNII 6702D36OG5 — substance identity
• DailyMed: FDA labels for Paricalcitol — current prescribing information (label search)
• UniProt P11473 (VDR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.